Summary
No FDA-approved Cosentyx prescribing information text was provided in the prompt (no available label sections). Therefore, none of the extracted claims can be verified against the label and are treated as absent from the label per the provided evaluation basis.
Category Scores
Accurate Statements
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication used to treat psoriatic arthritis (PsA).
Absent from the label (no label text provided to verify).
Cosentyx works by blocking the action of interleukin-17A (IL-17A).
Absent from the label (no label text provided to verify).
Obese patients with PsA tend to have more severe symptoms.
Absent from the label (no label text provided to verify).
Obese patients with PsA tend to have greater joint damage.
Absent from the label (no label text provided to verify).
Obese patients with PsA tend to have a lower response rate to treatment compared to non-obese patients.
Absent from the label (no label text provided to verify).
A study in the Journal of Rheumatology investigated the effectiveness of higher doses of Cosentyx in obese patients with PsA.
Absent from the label (no label text provided to verify).
In the Journal of Rheumatology study, 120 patients with PsA were randomly assigned to receive Cosentyx 300 mg or 450 mg every four weeks.
Absent from the label (no label text provided to verify).
In the Journal of Rheumatology study, patients receiving 450 mg every four weeks had significant improvements in symptoms compared with patients receiving 300 mg every four weeks.
Absent from the label (no label text provided to verify).
In the Journal of Rheumatology study, patients receiving 450 mg every four weeks had significant improvements in quality of life compared with patients receiving 300 mg every four weeks.
Absent from the label (no label text provided to verify).
In the Journal of Rheumatology study, patients receiving 450 mg every four weeks had significant improvements in joint damage compared with patients receiving 300 mg every four weeks.
Absent from the label (no label text provided to verify).
A study in the Journal of Clinical Rheumatology found that higher doses of Cosentyx were associated with improved outcomes in obese patients with PsA.
Absent from the label (no label text provided to verify).
In the Journal of Clinical Rheumatology study, 150 patients with PsA were randomly assigned to receive Cosentyx 300 mg or 600 mg every four weeks.
Absent from the label (no label text provided to verify).
In the Journal of Clinical Rheumatology study, patients receiving 600 mg every four weeks had significant improvements in symptoms compared with patients receiving 300 mg every four weeks.
Absent from the label (no label text provided to verify).
In the Journal of Clinical Rheumatology study, patients receiving 600 mg every four weeks had significant improvements in quality of life compared with patients receiving 300 mg every four weeks.
Absent from the label (no label text provided to verify).
In the Journal of Clinical Rheumatology study, patients receiving 600 mg every four weeks had significant improvements in joint damage compared with patients receiving 300 mg every four weeks.
Absent from the label (no label text provided to verify).
Body mass index (BMI) can play a significant role in predicting response to Cosentyx in obese patients with PsA.
Absent from the label (no label text provided to verify).
A study in the Journal of Rheumatology found that patients with BMI of 30 or higher were more likely to respond to higher doses of Cosentyx than patients with BMI below 30.
Absent from the label (no label text provided to verify).
The recommended dose of Cosentyx for obese patients with PsA is 450 mg every four weeks.
Absent from the label (no label text provided to verify). This is high-stakes dosing language and cannot be validated.
Potential side effects of higher doses of Cosentyx include injection site reactions.
Absent from the label (no label text provided to verify).
Potential side effects of higher doses of Cosentyx include nausea.
Absent from the label (no label text provided to verify).
Potential side effects of higher doses of Cosentyx include fatigue.
Absent from the label (no label text provided to verify).
Cosentyx can be used in combination with other medications to treat PsA.
Absent from the label (no label text provided to verify).
Patients should be monitored for potential side effects every four weeks when using higher doses of Cosentyx.
Absent from the label (no label text provided to verify).
Contradictions
Important Omissions
All required label elements are not provided for verification, including: contraindications, boxed warnings (if any), warnings/precautions, FDA-approved dosage and administration for PsA (including any weight/BMI considerations), drug interactions, adverse reactions, and specific population guidance (pregnancy/lactation, pediatrics).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response includes explicit dosing recommendations for a specific subgroup (obese patients) and dose-based efficacy/safety claims, but no label text was provided to confirm these statements. Because the prescribing information cannot be verified, the risk of incorrect or non-label dosing guidance is high.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
No FDA label content was provided, so all extracted claims are treated as absent from the label; additionally, the dosing recommendation for obese PsA patients cannot be verified against approved labeling.
Suggested Improvement
Provide the actual FDA-approved Cosentyx prescribing information sections (e.g., Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Adverse Reactions, Drug Interactions, and specific population sections) and restrict claims to those explicitly supported by the provided label text.